Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study

P1093 is a multicenter, open-label, phase I/II study of pharmacokinetics, safety, and tolerability of dolutegravir plus an optimized background regimen in pediatric participants aged 4 weeks to <18 years with HIV-1. Most participants were highly treatment experienced. We report the mechanisms of...

Descripción completa

Detalles Bibliográficos
Autores principales: Vavro, Cindy, Ruel, Theodore, Wiznia, Andrew, Montañez, Nicole, Nangle, Keith, Horton, Joseph, Buchanan, Ann M., Stewart, Eugene L., Palumbo, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765298/
https://www.ncbi.nlm.nih.gov/pubmed/34694878
http://dx.doi.org/10.1128/AAC.01645-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765298/
https://www.ncbi.nlm.nih.gov/pubmed/34694878
http://dx.doi.org/10.1128/AAC.01645-21

Ejemplares similares